Click for best price
Myelodysplastic Syndrome Treatment Market Size, Share 2023
This report contains market size and forecasts of Myelodysplastic Syndrome Treatment in Global, including the following market information:
The global Myelodysplastic Syndrome Treatment market was valued at million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
Allogeneic Stem Cell Transplantation Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Myelodysplastic Syndrome Treatment include AbbVie Inc., Bristol-Myers Squibb, Accord Healthcare, Jazz Pharmaceuticals Inc., Novartis AG, Lupin Pharmaceuticals, Otsuka America Pharmaceutical Inc., Onconova Therapeutics and Takeda Pharmaceutical Company Limited, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Myelodysplastic Syndrome Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Myelodysplastic Syndrome Treatment Market, by Treatment Method, 2018-2023, 2023-2030 ($ millions)
Global Myelodysplastic Syndrome Treatment Market Segment Percentages, by Treatment Method, 2022 (%)
- Allogeneic Stem Cell Transplantation
- Autologous Stem Cell Transplantation
Global Myelodysplastic Syndrome Treatment Market, by Application, 2018-2023, 2023-2030 ($ millions)
Global Myelodysplastic Syndrome Treatment Market Segment Percentages, by Application, 2022 (%)
Global Myelodysplastic Syndrome Treatment Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions)
Global Myelodysplastic Syndrome Treatment Market Segment Percentages, By Region and Country, 2022 (%)
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Nordic Countries
- Benelux
- Rest of Europe
- Asia
- China
- Japan
- South Korea
- Southeast Asia
- India
- Rest of Asia
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- Turkey
- Israel
- Saudi Arabia
- UAE
- Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
- Key companies Myelodysplastic Syndrome Treatment revenues in global market, 2018-2023 (estimated), ($ millions)
- Key companies Myelodysplastic Syndrome Treatment revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
- AbbVie Inc.
- Bristol-Myers Squibb
- Accord Healthcare
- Jazz Pharmaceuticals Inc.
- Novartis AG
- Lupin Pharmaceuticals
- Otsuka America Pharmaceutical Inc.
- Onconova Therapeutics
- Takeda Pharmaceutical Company Limited
- Astex Pharmaceuticals, Inc.
- Amgen Inc.
- Hikma Pharmaceuticals PLC
| Report Attributes |
Report Details |
| Report Title |
Myelodysplastic Syndrome Treatment Market, Global Outlook and Forecast 2023-2030 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2022 |
| Forecast Year |
2030 |
| Number of Pages |
62 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Myelodysplastic Syndrome Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Treatment Method
1.2.2 Market by Application
1.3 Global Myelodysplastic Syndrome Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Myelodysplastic Syndrome Treatment Overall Market Size
2.1 Global Myelodysplastic Syndrome Treatment Market Size: 2022 VS 2030
2.2 Global Myelodysplastic Syndrome Treatment Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Myelodysplastic Syndrome Treatment Players in Global Market
3.2 Top Global Myelodysplastic Syndrome Treatment Companies Ranked by Revenue
3.3 Global Myelodysplastic Syndrome Treatment Revenue by Companies
3.4 Top 3 and Top 5 Myelodysplastic Syndrome Treatment Companies in Global Market, by Revenue in 2022
3.5 Global Companies Myelodysplastic Syndrome Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Myelodysplastic Syndrome Treatment Players in Global Market
3.6.1 List of Global Tier 1 Myelodysplastic Syndrome Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Myelodysplastic Syndrome Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Treatment Method - Global Myelodysplastic Syndrome Treatment Market Size Markets, 2022 & 2030
4.1.2 Allogeneic Stem Cell Transplantation
4.1.3 Autologous Stem Cell Transplantation
4.2 By Treatment Method - Global Myelodysplastic Syndrome Treatment Revenue & Forecasts
4.2.1 By Treatment Method - Global Myelodysplastic Syndrome Treatment Revenue, 2018-2023
4.2.2 By Treatment Method - Global Myelodysplastic Syndrome Treatment Revenue, 2023-2030
4.2.3 By Treatment Method - Global Myelodysplastic Syndrome Treatment Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Myelodysplastic Syndrome Treatment Market Size, 2022 & 2030
5.1.2 Hospitals
5.1.3 Clinics
5.1.4 Others
5.2 By Application - Global Myelodysplastic Syndrome Treatment Revenue & Forecasts
5.2.1 By Application - Global Myelodysplastic Syndrome Treatment Revenue, 2018-2023
5.2.2 By Application - Global Myelodysplastic Syndrome Treatment Revenue, 2023-2030
5.2.3 By Application - Global Myelodysplastic Syndrome Treatment Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Myelodysplastic Syndrome Treatment Market Size, 2022 & 2030
6.2 By Region - Global Myelodysplastic Syndrome Treatment Revenue & Forecasts
6.2.1 By Region - Global Myelodysplastic Syndrome Treatment Revenue, 2018-2023
6.2.2 By Region - Global Myelodysplastic Syndrome Treatment Revenue, 2023-2030
6.2.3 By Region - Global Myelodysplastic Syndrome Treatment Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Myelodysplastic Syndrome Treatment Revenue, 2018-2030
6.3.2 US Myelodysplastic Syndrome Treatment Market Size, 2018-2030
6.3.3 Canada Myelodysplastic Syndrome Treatment Market Size, 2018-2030
6.3.4 Mexico Myelodysplastic Syndrome Treatment Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Myelodysplastic Syndrome Treatment Revenue, 2018-2030
6.4.2 Germany Myelodysplastic Syndrome Treatment Market Size, 2018-2030
6.4.3 France Myelodysplastic Syndrome Treatment Market Size, 2018-2030
6.4.4 U.K. Myelodysplastic Syndrome Treatment Market Size, 2018-2030
6.4.5 Italy Myelodysplastic Syndrome Treatment Market Size, 2018-2030
6.4.6 Russia Myelodysplastic Syndrome Treatment Market Size, 2018-2030
6.4.7 Nordic Countries Myelodysplastic Syndrome Treatment Market Size, 2018-2030
6.4.8 Benelux Myelodysplastic Syndrome Treatment Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Myelodysplastic Syndrome Treatment Revenue, 2018-2030
6.5.2 China Myelodysplastic Syndrome Treatment Market Size, 2018-2030
6.5.3 Japan Myelodysplastic Syndrome Treatment Market Size, 2018-2030
6.5.4 South Korea Myelodysplastic Syndrome Treatment Market Size, 2018-2030
6.5.5 Southeast Asia Myelodysplastic Syndrome Treatment Market Size, 2018-2030
6.5.6 India Myelodysplastic Syndrome Treatment Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Myelodysplastic Syndrome Treatment Revenue, 2018-2030
6.6.2 Brazil Myelodysplastic Syndrome Treatment Market Size, 2018-2030
6.6.3 Argentina Myelodysplastic Syndrome Treatment Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Myelodysplastic Syndrome Treatment Revenue, 2018-2030
6.7.2 Turkey Myelodysplastic Syndrome Treatment Market Size, 2018-2030
6.7.3 Israel Myelodysplastic Syndrome Treatment Market Size, 2018-2030
6.7.4 Saudi Arabia Myelodysplastic Syndrome Treatment Market Size, 2018-2030
6.7.5 UAE Myelodysplastic Syndrome Treatment Market Size, 2018-2030
7 Players Profiles
7.1 AbbVie Inc.
7.1.1 AbbVie Inc. Corporate Summary
7.1.2 AbbVie Inc. Business Overview
7.1.3 AbbVie Inc. Myelodysplastic Syndrome Treatment Major Product Offerings
7.1.4 AbbVie Inc. Myelodysplastic Syndrome Treatment Revenue in Global Market (2018-2023)
7.1.5 AbbVie Inc. Key News
7.2 Bristol-Myers Squibb
7.2.1 Bristol-Myers Squibb Corporate Summary
7.2.2 Bristol-Myers Squibb Business Overview
7.2.3 Bristol-Myers Squibb Myelodysplastic Syndrome Treatment Major Product Offerings
7.2.4 Bristol-Myers Squibb Myelodysplastic Syndrome Treatment Revenue in Global Market (2018-2023)
7.2.5 Bristol-Myers Squibb Key News
7.3 Accord Healthcare
7.3.1 Accord Healthcare Corporate Summary
7.3.2 Accord Healthcare Business Overview
7.3.3 Accord Healthcare Myelodysplastic Syndrome Treatment Major Product Offerings
7.3.4 Accord Healthcare Myelodysplastic Syndrome Treatment Revenue in Global Market (2018-2023)
7.3.5 Accord Healthcare Key News
7.4 Jazz Pharmaceuticals Inc.
7.4.1 Jazz Pharmaceuticals Inc. Corporate Summary
7.4.2 Jazz Pharmaceuticals Inc. Business Overview
7.4.3 Jazz Pharmaceuticals Inc. Myelodysplastic Syndrome Treatment Major Product Offerings
7.4.4 Jazz Pharmaceuticals Inc. Myelodysplastic Syndrome Treatment Revenue in Global Market (2018-2023)
7.4.5 Jazz Pharmaceuticals Inc. Key News
7.5 Novartis AG
7.5.1 Novartis AG Corporate Summary
7.5.2 Novartis AG Business Overview
7.5.3 Novartis AG Myelodysplastic Syndrome Treatment Major Product Offerings
7.5.4 Novartis AG Myelodysplastic Syndrome Treatment Revenue in Global Market (2018-2023)
7.5.5 Novartis AG Key News
7.6 Lupin Pharmaceuticals
7.6.1 Lupin Pharmaceuticals Corporate Summary
7.6.2 Lupin Pharmaceuticals Business Overview
7.6.3 Lupin Pharmaceuticals Myelodysplastic Syndrome Treatment Major Product Offerings
7.6.4 Lupin Pharmaceuticals Myelodysplastic Syndrome Treatment Revenue in Global Market (2018-2023)
7.6.5 Lupin Pharmaceuticals Key News
7.7 Otsuka America Pharmaceutical Inc.
7.7.1 Otsuka America Pharmaceutical Inc. Corporate Summary
7.7.2 Otsuka America Pharmaceutical Inc. Business Overview
7.7.3 Otsuka America Pharmaceutical Inc. Myelodysplastic Syndrome Treatment Major Product Offerings
7.7.4 Otsuka America Pharmaceutical Inc. Myelodysplastic Syndrome Treatment Revenue in Global Market (2018-2023)
7.7.5 Otsuka America Pharmaceutical Inc. Key News
7.8 Onconova Therapeutics
7.8.1 Onconova Therapeutics Corporate Summary
7.8.2 Onconova Therapeutics Business Overview
7.8.3 Onconova Therapeutics Myelodysplastic Syndrome Treatment Major Product Offerings
7.8.4 Onconova Therapeutics Myelodysplastic Syndrome Treatment Revenue in Global Market (2018-2023)
7.8.5 Onconova Therapeutics Key News
7.9 Takeda Pharmaceutical Company Limited
7.9.1 Takeda Pharmaceutical Company Limited Corporate Summary
7.9.2 Takeda Pharmaceutical Company Limited Business Overview
7.9.3 Takeda Pharmaceutical Company Limited Myelodysplastic Syndrome Treatment Major Product Offerings
7.9.4 Takeda Pharmaceutical Company Limited Myelodysplastic Syndrome Treatment Revenue in Global Market (2018-2023)
7.9.5 Takeda Pharmaceutical Company Limited Key News
7.10 Astex Pharmaceuticals, Inc.
7.10.1 Astex Pharmaceuticals, Inc. Corporate Summary
7.10.2 Astex Pharmaceuticals, Inc. Business Overview
7.10.3 Astex Pharmaceuticals, Inc. Myelodysplastic Syndrome Treatment Major Product Offerings
7.10.4 Astex Pharmaceuticals, Inc. Myelodysplastic Syndrome Treatment Revenue in Global Market (2018-2023)
7.10.5 Astex Pharmaceuticals, Inc. Key News
7.11 Amgen Inc.
7.11.1 Amgen Inc. Corporate Summary
7.11.2 Amgen Inc. Business Overview
7.11.3 Amgen Inc. Myelodysplastic Syndrome Treatment Major Product Offerings
7.11.4 Amgen Inc. Myelodysplastic Syndrome Treatment Revenue in Global Market (2018-2023)
7.11.5 Amgen Inc. Key News
7.12 Hikma Pharmaceuticals PLC
7.12.1 Hikma Pharmaceuticals PLC Corporate Summary
7.12.2 Hikma Pharmaceuticals PLC Business Overview
7.12.3 Hikma Pharmaceuticals PLC Myelodysplastic Syndrome Treatment Major Product Offerings
7.12.4 Hikma Pharmaceuticals PLC Myelodysplastic Syndrome Treatment Revenue in Global Market (2018-2023)
7.12.5 Hikma Pharmaceuticals PLC Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Myelodysplastic Syndrome Treatment Market Opportunities & Trends in Global Market
Table 2. Myelodysplastic Syndrome Treatment Market Drivers in Global Market
Table 3. Myelodysplastic Syndrome Treatment Market Restraints in Global Market
Table 4. Key Players of Myelodysplastic Syndrome Treatment in Global Market
Table 5. Top Myelodysplastic Syndrome Treatment Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Myelodysplastic Syndrome Treatment Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Myelodysplastic Syndrome Treatment Revenue Share by Companies, 2018-2023
Table 8. Global Companies Myelodysplastic Syndrome Treatment Product Type
Table 9. List of Global Tier 1 Myelodysplastic Syndrome Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Myelodysplastic Syndrome Treatment Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Treatment Method ? Global Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2022 & 2030
Table 12. By Treatment Method - Myelodysplastic Syndrome Treatment Revenue in Global (US$, Mn), 2018-2023
Table 13. By Treatment Method - Myelodysplastic Syndrome Treatment Revenue in Global (US$, Mn), 2023-2030
Table 14. By Application ? Global Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Myelodysplastic Syndrome Treatment Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Myelodysplastic Syndrome Treatment Revenue in Global (US$, Mn), 2023-2030
Table 17. By Region ? Global Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Myelodysplastic Syndrome Treatment Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Myelodysplastic Syndrome Treatment Revenue (US$, Mn), 2023-2030
Table 20. By Country - North America Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2023-2030
Table 22. By Country - Europe Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2023-2030
Table 24. By Region - Asia Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2023-2030
Table 26. By Country - South America Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2023-2030
Table 28. By Country - Middle East & Africa Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2023-2030
Table 30. AbbVie Inc. Corporate Summary
Table 31. AbbVie Inc. Myelodysplastic Syndrome Treatment Product Offerings
Table 32. AbbVie Inc. Myelodysplastic Syndrome Treatment Revenue (US$, Mn), (2018-2023)
Table 33. Bristol-Myers Squibb Corporate Summary
Table 34. Bristol-Myers Squibb Myelodysplastic Syndrome Treatment Product Offerings
Table 35. Bristol-Myers Squibb Myelodysplastic Syndrome Treatment Revenue (US$, Mn), (2018-2023)
Table 36. Accord Healthcare Corporate Summary
Table 37. Accord Healthcare Myelodysplastic Syndrome Treatment Product Offerings
Table 38. Accord Healthcare Myelodysplastic Syndrome Treatment Revenue (US$, Mn), (2018-2023)
Table 39. Jazz Pharmaceuticals Inc. Corporate Summary
Table 40. Jazz Pharmaceuticals Inc. Myelodysplastic Syndrome Treatment Product Offerings
Table 41. Jazz Pharmaceuticals Inc. Myelodysplastic Syndrome Treatment Revenue (US$, Mn), (2018-2023)
Table 42. Novartis AG Corporate Summary
Table 43. Novartis AG Myelodysplastic Syndrome Treatment Product Offerings
Table 44. Novartis AG Myelodysplastic Syndrome Treatment Revenue (US$, Mn), (2018-2023)
Table 45. Lupin Pharmaceuticals Corporate Summary
Table 46. Lupin Pharmaceuticals Myelodysplastic Syndrome Treatment Product Offerings
Table 47. Lupin Pharmaceuticals Myelodysplastic Syndrome Treatment Revenue (US$, Mn), (2018-2023)
Table 48. Otsuka America Pharmaceutical Inc. Corporate Summary
Table 49. Otsuka America Pharmaceutical Inc. Myelodysplastic Syndrome Treatment Product Offerings
Table 50. Otsuka America Pharmaceutical Inc. Myelodysplastic Syndrome Treatment Revenue (US$, Mn), (2018-2023)
Table 51. Onconova Therapeutics Corporate Summary
Table 52. Onconova Therapeutics Myelodysplastic Syndrome Treatment Product Offerings
Table 53. Onconova Therapeutics Myelodysplastic Syndrome Treatment Revenue (US$, Mn), (2018-2023)
Table 54. Takeda Pharmaceutical Company Limited Corporate Summary
Table 55. Takeda Pharmaceutical Company Limited Myelodysplastic Syndrome Treatment Product Offerings
Table 56. Takeda Pharmaceutical Company Limited Myelodysplastic Syndrome Treatment Revenue (US$, Mn), (2018-2023)
Table 57. Astex Pharmaceuticals, Inc. Corporate Summary
Table 58. Astex Pharmaceuticals, Inc. Myelodysplastic Syndrome Treatment Product Offerings
Table 59. Astex Pharmaceuticals, Inc. Myelodysplastic Syndrome Treatment Revenue (US$, Mn), (2018-2023)
Table 60. Amgen Inc. Corporate Summary
Table 61. Amgen Inc. Myelodysplastic Syndrome Treatment Product Offerings
Table 62. Amgen Inc. Myelodysplastic Syndrome Treatment Revenue (US$, Mn), (2018-2023)
Table 63. Hikma Pharmaceuticals PLC Corporate Summary
Table 64. Hikma Pharmaceuticals PLC Myelodysplastic Syndrome Treatment Product Offerings
Table 65. Hikma Pharmaceuticals PLC Myelodysplastic Syndrome Treatment Revenue (US$, Mn), (2018-2023)
List of Figures
Figure 1. Myelodysplastic Syndrome Treatment Segment by Treatment Method in 2022
Figure 2. Myelodysplastic Syndrome Treatment Segment by Application in 2022
Figure 3. Global Myelodysplastic Syndrome Treatment Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Myelodysplastic Syndrome Treatment Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Myelodysplastic Syndrome Treatment Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Myelodysplastic Syndrome Treatment Revenue in 2022
Figure 8. By Treatment Method - Global Myelodysplastic Syndrome Treatment Revenue Market Share, 2018-2030
Figure 9. By Application - Global Myelodysplastic Syndrome Treatment Revenue Market Share, 2018-2030
Figure 10. By Region - Global Myelodysplastic Syndrome Treatment Revenue Market Share, 2018-2030
Figure 11. By Country - North America Myelodysplastic Syndrome Treatment Revenue Market Share, 2018-2030
Figure 12. US Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 13. Canada Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 14. Mexico Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 15. By Country - Europe Myelodysplastic Syndrome Treatment Revenue Market Share, 2018-2030
Figure 16. Germany Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 17. France Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 18. U.K. Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 19. Italy Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 20. Russia Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 21. Nordic Countries Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 22. Benelux Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 23. By Region - Asia Myelodysplastic Syndrome Treatment Revenue Market Share, 2018-2030
Figure 24. China Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 25. Japan Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 26. South Korea Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 27. Southeast Asia Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 28. India Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 29. By Country - South America Myelodysplastic Syndrome Treatment Revenue Market Share, 2018-2030
Figure 30. Brazil Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 31. Argentina Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 32. By Country - Middle East & Africa Myelodysplastic Syndrome Treatment Revenue Market Share, 2018-2030
Figure 33. Turkey Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 34. Israel Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 35. Saudi Arabia Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 36. UAE Myelodysplastic Syndrome Treatment Revenue, (US$, Mn), 2018-2030
Figure 37. AbbVie Inc. Myelodysplastic Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 38. Bristol-Myers Squibb Myelodysplastic Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 39. Accord Healthcare Myelodysplastic Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 40. Jazz Pharmaceuticals Inc. Myelodysplastic Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 41. Novartis AG Myelodysplastic Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Lupin Pharmaceuticals Myelodysplastic Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Otsuka America Pharmaceutical Inc. Myelodysplastic Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Onconova Therapeutics Myelodysplastic Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Takeda Pharmaceutical Company Limited Myelodysplastic Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Astex Pharmaceuticals, Inc. Myelodysplastic Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Amgen Inc. Myelodysplastic Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Hikma Pharmaceuticals PLC Myelodysplastic Syndrome Treatment Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
